Diabetic Foot Ulcers - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 129 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Diabetic Foot Ulcers - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Diabetic Foot Ulcers - Pipeline Review, H2 2014', provides an overview of the Diabetic Foot Ulcers's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Foot Ulcers and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Foot Ulcers pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diabetic Foot Ulcers Overview 10
Therapeutics Development 11
Pipeline Products for Diabetic Foot Ulcers - Overview 11
Pipeline Products for Diabetic Foot Ulcers - Comparative Analysis 12
Diabetic Foot Ulcers - Therapeutics under Development by Companies 13
Diabetic Foot Ulcers - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Diabetic Foot Ulcers - Products under Development by Companies 20
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 22
Derma Sciences, Inc. 22
GlaxoSmithKline plc 23
CardioVascular BioTherapeutics, Inc. 24
Stratatech Corporation 25
Tissue Med Biosciences 26
Reliance Life Sciences Pvt. Ltd. 27
Celgene Corporation 28
Kaken Pharmaceutical Co., Ltd. 29
CytoTools AG 30
NovaLead Pharma Pvt. Ltd. 31
FirstString Research, Inc. 32
Lumosa Therapeutics Co., Ltd. 33
CoDa Therapeutics, Inc. 34
Adocia 35
Plurogen Therapeutics, Inc. 36
EyeGene, Inc. 37
Izun Pharmaceuticals Corporation 38
MacroCure 39
Royer Biomedical, Inc. 40
Oneness Biotech Co., Ltd. 41
Aprogen, Inc. 42
Pergamum AB 43
Dipexium Pharmaceuticals LLC 44
Kasiak Research Pvt. Ltd. 45
Innovaxis 46
Grupo Praxis Pharmaceutical SA 47
Diabetic Foot Ulcers - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Target 49
Assessment by Mechanism of Action 52
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 60
pexiganan acetate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
DermaPro - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
trafermin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ON-101 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DSC-127 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CureXcell - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Granexin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Vivefoot - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
ReliDerm-DT - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
CVBT-141B - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
CODA-001 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PX-070101 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
IZN-6D4 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CSTC-1 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PluroGel N - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
esmolol hydrochloride - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
gentamicin sulfate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
GSK-1278863 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
PDA-002 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TMBP-3 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
coagulation factor XIVa (human) - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
AP-102 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Cyndacel-M - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
EG-Decorin - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
STD-06 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Nu-2 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Nu-3 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
MT-003 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Cathelicidin - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
IMSP-001 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Drug for Diabetic Foot Ulcer - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
LL-37 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Refaheal - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Diabetic Foot Ulcers - Recent Pipeline Updates 108
Diabetic Foot Ulcers - Dormant Projects 119
Diabetic Foot Ulcers - Discontinued Products 120
Diabetic Foot Ulcers - Product Development Milestones 121
Featured News & Press Releases 121
Sep 02, 2014: Macrocure Completes Enrollment in Pivotal Phase III Clinical Trial of CureXcell in Diabetic Foot Ulcers 121
Aug 25, 2014: Adocia Launches Phase III Clinical Study In India Of Treatment For Diabetic Foot Ulcer 121
Jul 25, 2014: Clinical development of wound healing drug DermaPro progressing on schedule in Europe 122
Jul 21, 2014: Dipexium Pharmaceuticals Initiates Second of Two Pivotal Phase 3 Clinical Trials of Locilex in Patients with Mild Infections of Diabetic Foot Ulcers 122
Jul 17, 2014: Dipexium Pharmaceuticals Announces Successful Completion of Phase 1 Skin Irritation Trial of Locilex 123
Jul 17, 2014: Dipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Locilex in Patients with Mild Infections of Diabetic Foot Ulcers 124
May 21, 2014: MediWound Initiates Second Phase 2 Clinical Trial of EscharEx to Treat Chronic and Other Hard-to-Heal Wounds 125
Jan 16, 2014: Derma Sciences Provides Update on DSC127 Phase 3 Clinical Trials 125
Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers 126
Sep 10, 2013: Dipexium Provides Locilex Manufacturing Update 127
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 129
Disclaimer 129

List of Tables
Number of Products under Development for Diabetic Foot Ulcers, H2 2014 11
Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Comparative Analysis by Unknown Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Development by Companies, H2 2014 (Contd..1) 21
Diabetic Foot Ulcers - Pipeline by Derma Sciences, Inc., H2 2014 22
Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline plc, H2 2014 23
Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2014 24
Diabetic Foot Ulcers - Pipeline by Stratatech Corporation, H2 2014 25
Diabetic Foot Ulcers - Pipeline by Tissue Med Biosciences, H2 2014 26
Diabetic Foot Ulcers - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2014 27
Diabetic Foot Ulcers - Pipeline by Celgene Corporation, H2 2014 28
Diabetic Foot Ulcers - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2014 29
Diabetic Foot Ulcers - Pipeline by CytoTools AG, H2 2014 30
Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2014 31
Diabetic Foot Ulcers - Pipeline by FirstString Research, Inc., H2 2014 32
Diabetic Foot Ulcers - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2014 33
Diabetic Foot Ulcers - Pipeline by CoDa Therapeutics, Inc., H2 2014 34
Diabetic Foot Ulcers - Pipeline by Adocia, H2 2014 35
Diabetic Foot Ulcers - Pipeline by Plurogen Therapeutics, Inc., H2 2014 36
Diabetic Foot Ulcers - Pipeline by EyeGene, Inc., H2 2014 37
Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corporation, H2 2014 38
Diabetic Foot Ulcers - Pipeline by MacroCure, H2 2014 39
Diabetic Foot Ulcers - Pipeline by Royer Biomedical, Inc. , H2 2014 40
Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co., Ltd., H2 2014 41
Diabetic Foot Ulcers - Pipeline by Aprogen, Inc., H2 2014 42
Diabetic Foot Ulcers - Pipeline by Pergamum AB, H2 2014 43
Diabetic Foot Ulcers - Pipeline by Dipexium Pharmaceuticals LLC, H2 2014 44
Diabetic Foot Ulcers - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 45
Diabetic Foot Ulcers - Pipeline by Innovaxis, H2 2014 46
Diabetic Foot Ulcers - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2014 47
Assessment by Monotherapy Products, H2 2014 48
Number of Products by Stage and Target, H2 2014 51
Number of Products by Stage and Mechanism of Action, H2 2014 54
Number of Products by Stage and Route of Administration, H2 2014 56
Number of Products by Stage and Molecule Type, H2 2014 59
Diabetic Foot Ulcers Therapeutics - Recent Pipeline Updates, H2 2014 108
Diabetic Foot Ulcers - Dormant Projects, H2 2014 119
Diabetic Foot Ulcers - Discontinued Products, H2 2014 120